Emerging pharmacotherapy of tinnitus

Expert Opinion on Emerging Drugs

Volumn 14, Issue 4, 2009, Pages 687-702

  Langguth, Berthold ^a   Salvi, Richard ^b   Elgoyhen, Ana Beln ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anticonvulsants; Antidepressants; Anxiolytics; Auditory system; GABA; Glutamate; Hearing; Inner ear; NMDA; Pain; Phantom perception

Indexed keywords

ACAMPROSATE; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETAHISTINE; CARBAMAZEPINE; CAROVERINE; CINNARIZINE; CLONAZEPAM; DIHYDROERGOCRISTINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUNARIZINE; GINKGO BILOBA EXTRACT; LIDOCAINE; MELATONIN; NERAMEXANE; NICERGOLINE; NIMODIPINE; PENTOXIFYLLINE; PIRACETAM; PIRIBEDIL; PLACEBO; PREDNISOLONE; SULPIRIDE; TOCAINIDE; UNINDEXED DRUG;

ALCOHOLISM; ANXIETY; AUDITORY STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESEARCH; HEART ARRHYTHMIA; HUMAN; INSOMNIA; LOW DRUG DOSE; NONHUMAN; OFF LABEL DRUG USE; QUALITY OF LIFE; REVIEW; SUBARACHNOID HEMORRHAGE; TINNITUS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; BODY MASS INDEX; COGNITION DISORDERS; COGNITIVE THERAPY; DEPRESSION; DEPRESSIVE DISORDER; HEALTH STATUS; HUMANS; IRRITABLE MOOD; LUNG NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CANNABINOID; RISK FACTORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; TINNITUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 71649104369     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903206975     Document Type: Review

References (199)

1. Henry JA, Dennis KC, Schechter MA. General review of tinnitus: Prevalence, mechanisms, effects, and management. J Speech Lang Hear Res 2005;48(5):1204-1235
2. Axelsson A, Ringdahl A. Tinnitus-a study of its prevalence and characteristics. Br J Audiol 1989;23(1):53-62
3. Hoffman HJ, Reed GW. Epidemiology of Tinnitus. In: Snow JB, editor, Tinnitus: Theory and management. London: BC Decker; 2004. p. 16-41
4. Vio MM, Holme RH. Hearing loss and tinnitus: 250 million people and a US$10 billion potential market. Drug Discov Today 2005;10(19):1263-1265
5. Norena A, Micheyl C, Chery-Croze S, Collet L. Psychoacoustic characterization of the tinnitus spectrum: implications for the underlying mechanisms of tinnitus. Audiol Neurootol 2002;7(6):358-369
6. Roberts LE, Moffat G, Bosnyak DJ. Residual inhibition functions in relation to tinnitus spectra and auditory threshold shift. Acta Otolaryngol Suppl 2006;556:27-33
7. Konig O, Schaette R, Kempter R, Gross M. Course of hearing loss and occurrence of tinnitus. Hear Res 2006;221(1-2):59-64
8. House JW, Brackmann DE. Tinnitus: Surgical treatment. Ciba Found Symp 1981;85:204-216
9. Heller MF, Bergman M. Tinnitus aurium in normally hearing persons. Ann Otol Rhinol Laryngol 1953;62(1):73-83
10. Del Bo L, Forti S, Ambrosetti U, et al. Tinnitus aurium in persons with normal hearing: 55 years later. Otolaryngol Head Neck Surg 2008;139(3):391-394
11. Langguth B, Goodey R, Azevedo A, et al. Consensus for tinnitus patient assessment and treatment outcome measurement: Tinnitus Research Initiative meeting, Regensburg, July 2006. Prog Brain Res 2007;166:525-536
12. Henry JA, Meikle MB. Psychoacoustic measures of tinnitus. J Am Acad Audiol 2000;11:138-155
13. Vernon JA, Meikle MB. Tinnitus: clinical measurement. Otolaryngol Clin North Am 2003;36(2):293-305, vi
14. Tyler RS, Oleson J, Noble W, et al. Clinical trials for tinnitus: Study populations, designs, measurement variables, and data analysis. Prog Brain Res 2007;166:499-509
15. Hiller W, Goebel G. Factors influencing tinnitus loudness and annoyance. Arch Otolaryngol Head Neck Surg 2006;132(12):1323-1330
16. Jastreboff PJ. Phantom auditory perception (tinnitus): mechanisms of generation and perception. Neurosci Res 1990;8:221-254
17. Moller AR. Pathophysiology of tinnitus. Otolaryngol Clin North Am 2003;36:249-266
18. Bauer CA, Turner JG, Caspary DM, et al. Tinnitus and inferior colliculus activity in chinchillas related to three distinct patterns of cochlear trauma. J Neurosci Res 2008;86(11):2564-2578
19. Eggermont JJ. Pathophysiology of tinnitus. Prog Brain Res 2007;166:19-35
20. Kaltenbach JA. The dorsal cochlear nucleus as a contributor to tinnitus: mechanisms underlying the induction of hyperactivity. Prog Brain Res 2007;166:89-106
21. Melcher JR, Sigalovsky IS, Guinan JJ Jr, Levine RA. Lateralized tinnitus studied with functional magnetic resonance imaging: Abnormal inferior colliculus activation. J Neurophysiol 2000;83:1058-1072
22. Reyes SA, Salvi RJ, Burkard RF, et al. Brain imaging of the effects of lidocaine on tinnitus. Hear Res 2002;171:43-50
23. Langguth B, Eichhammer P, Kreutzer A, et al. The impact of auditory cortex activity on characterizing and treating patients with chronic tinnitus-first results from a PET study. Acta Otolaryngol Suppl 2006;(556):84-88
24. Smits M, Kovacs S, De RD, et al. Lateralization of functional magnetic resonance imaging (fMRI) activation in the auditory pathway of patients with lateralized tinnitus. Neuroradiology 2007;49(8):669-679
25. Schlee W, Hartmann T, Langguth B, Weisz N. Abnormal resting-state cortical coupling in chronic tinnitus. BMC Neurosci 2009;10(11)
26. Muroi Y, Chanda B. Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J Gen Physiol 2009;133(1):1-15
27. Trellakis S, Lautermann J, Lehnerdt G. Lidocaine: Neurobiological targets and effects on the auditory system. Prog Brain Res 2007;166:303-322
28. Cronlein T, Langguth B, Geisler P, Hajak G. Tinnitus and insomnia. Prog Brain Res 2007;166:227-233
29. Langguth B, Kleinjung T, Fischer B, et al. Tinnitus severity, depression, and the big five personality traits. Prog Brain Res 2007;166:221-225
30. Biassoni EC, Serra MR, Richtert U, et al. Recreational noise exposure and its effects on the hearing of adolescents. Part II: Development of hearing disorders. Int J Audiol 2005;44(2):74-85
31. Serra MR, Biassoni EC, Richter U, et al. Recreational noise exposure and its effects on the hearing of adolescents. Part I: An interdisciplinary long-term study. Int J Audiol 2005;44(2):65-73
32. Available from: http://www.vba.va.gov/bln/21/
33. Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202-1211
34. Dobie R. Clinical trials and drug therapy for tinnitus. In: Snow JB, editor. Tinnitus: Theory and management. Hamilton: BC Decker; 2004. p. 266-277
35. Vio M. Tinnitus market situation analysis. London: RNID, 2003
36. Eggermont JJ. Tinnitus: Neurobiological substrates. Drug Discov Today 2005;10(19):1283-1290
37. Moller AR. Tinnitus and pain. Prog Brain Res 2007;166:47-53
38. Moller AR. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus. Am J Otol 1997;18(2):268-269
39. Barany R. Die beeinflussung des ohrensausens durch intravenös injizierte lokalanästhetica. Acta Otolarngologica 1935;23:201-203
40. Melding PS, Goodey RJ, Thorne PR. The use of intravenous lignocaine in the diagnosis and treatment of tinnitus. J Laryngol Otol 1978;92(2):115-121
41. Martin FW, Colman BH. Tinnitus: A double-blind crossover controlled trial to evaluate the use of lignocaine. Clin Otolaryngol 1980;5:3-11
42. Sanchez TG, Balbani AP, Bittar RS, et al. Lidocaine test in patients with tinnitus: rationale of accomplishment and relation to the treatment with carbamazepine. Auris Nasus Larynx 1999;26(4):411-417
43. Trellakis S, Benzenberg D, Urban BW, Friederich P. Differential lidocaine sensitivity of human voltage-gated potassium channels relevant to the auditory system. Otol Neurotol 2006;27(1):117-123
44. Haginomori S, Makimoto K, Araki M, et al. Effect of lidocaine injection of EOAE in patients with tinnitus. Acta Otolaryngol 1995;115(4):488-492
45. Baguley DM, Jones S, Wilkins I, et al. The inhibitory effect of intravenous lidocaine infusion on tinnitus after translabyrinthine removal of vestibular schwannoma: A double-blind, placebo-controlled, crossover study. Otol Neurotol 2005;26(2):169-176
46. Schwartz ML, Meyer MB, Covino BG, et al. Antiarrhythmic effectiveness of intramuscular lidocaine: influence of different injection sites. J Clin Pharmacol 1974;14(2):77-83
47. Clarkson CW, Follmer CH, Ten EICK, et al. Evidence for two components of sodium channel block by lidocaine in isolated cardiac myocytes. Circ Res 1988;63(5):869-878
48. Courtney KR. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther 1975;195(2):225-236
49. Lenkowski PW, Shah BS, Dinn AE, et al. Lidocaine block of neonatal Nav1.3 is differentially modulated by co-expression of beta1 and beta3 subunits. Eur J Pharmacol 2003;467(1-3):23-30
50. Josephson IR. Lidocaine blocks Na, Ca and K currents of chick ventricular myocytes. J Mol Cell Cardiol 1988;20(7):593-604
51. Plewnia C, Reimold M, Najib A, et al. Dose-dependent attenuation of auditory phantom perception (tinnitus) by PET-guided repetitive transcranial magnetic stimulation. Hum Brain Mapp 2007;28(3):238-246
52. Hulshof JH, Vermeij P. The value of tocainide in the treatment of tinnitus. A double-blind controlled study. Arch Otorhinolaryngol 1985;241:279-283
53. Blayney AW, Phillips MS, Guy AM, Colman BH. A sequential double blind cross-over trial of tocainide hydrochloride in tinnitus. Clin Otolaryngol 1985;10:97-101
54. Lenarz T. Treatment of tinnitus with lidocaine and tocainide. Scand Audiol Suppl 1986;26:49-51 (Pubitemid 17229005)
55. Sieghart W. Pharmacology of benzodiazepine receptors: An update. J Psychiatry Neurosci 1994;19(1):24-29
56. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg 1993;119(8):842-845
57. Kay NJ. Oral chemotherapy in tinnitus. Br J Audiol 1981;15(2):123-124
58. Gananca MM, Caovilla HH, Gananca FF, et al. Clonazepam in the pharmacological treatment of vertigo and tinnitus. Int Tinnitus J 2002;8(1):50-53
59. Bahmad FM Jr, Venosa AR, Oliveira CA. Benzodiazepines and GABAergics in treating severe disabling tinnitus of predominantly cochlear origin. Int Tinnitus J 2006;12(2):140-144
60. Busto U, Fornazzari L, Naranjo CA. Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines. J Clin Psychopharmacol 1988;8(5):359-362
61. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315(14):854-859
62. Moller AR. Similarities between severe tinnitus and chronic pain. J Am Acad Audiol 2000;11:115-124
63. Gross G, Xin X, Gastpar M. Trimipramine: Pharmacological reevaluation and comparison with clozapine. Neuropharmacology 1991;30(11):1159-1166
64. Bayar N, Boke B, Turan E, Belgin E. Efficacy of amitriptyline in the treatment of subjective tinnitus. J Otolaryngol 2001;30(5):300-303
65. Podoshin L, Ben-David Y, Fradis M, et al. Idiopathic subjective tinnitus treated by amitriptyline hydrochloride/biofeedback. Int Tinnitus J 1995;1(1):54-60
66. Sullivan MD, Dobie RA, Sakai CS, Katon WJ. Treatment of depressed tinnitus patients with nortriptyline. Ann Otol Rhinol Laryngol 1989;98(11):867-872
67. Sullivan M, Katon W, Russo J, et al. A randomized trial of nortriptyline for severe chronic tinnitus. Effects on depression, disability, and tinnitus symptoms. Arch Intern Med 1993;153(19):2251-2259
68. Katon W, Sullivan M, Russo J, et al. Depressive symptoms and measures of disability: A prospective study. J Affect Disord 1993;27(4):245-254
69. Mihail RC, Crowley JM, Walden BE, et al. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol 1988;97(2 Pt 1):120-123
70. Mendis D, Johnston M. An unusual case of prolonged tinnitus following low-dose amitriptyline. J Psychopharmacol 2008;22(5):574-575
71. Feder R. Tinnitus associated with amitriptyline. J Clin Psychiatry 1990;51(2):85-86
72. Tandon R, Grunhaus L, Greden JF. Imipramine and tinnitus. J Clin Psychiatry 1987;48(3):109-111
73. Robinson SK, Viirre ES, Bailey KA, et al. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 2005;67(6):981-988
74. Zoger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering-a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2006;26(1):32-39
75. Robinson S. Antidepressants for treatment of tinnitus. Prog Brain Res 2007;166:263-271
76. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 1985;27(5):549-558
77. Cardenas CA, Cardenas CG, de Armendi AJ, Scroggs RS. Carbamazepine interacts with a slow inactivation state of NaV1.8-like sodium channels. Neurosci Lett 2006;408(2):129-134
78. Shea JJ, Harell M. Management of tinnitus aurium with lidocaine and carbamazepine. Laryngoscope 1978;88(9 Pt 1):1477-1484
79. Melding PS, Goodey RJ. The treatment of tinnitus with oral anticonvulsants. J Laryngol Otol 1979;93(2):111-122
80. Donaldson I. Tegretol: A double blind trial in tinnitus. J Laryngol Otol 1981;95(9):947-951
81. Hulshof JH, Vermeij P. The value of carbamazepine in the treatment of tinnitus. ORL J Otorhinolaryngol Relat Spec 1985;47:262-266
82. Marks NJ, Onisiphorou C, Trounce JR. The effect of single doses of amylobarbitone sodium and carbamazepine in tinnitus. J Laryngol Otol 1981;95(9):941-945
83. Levine RA. Typewriter tinnitus: A carbamazepine-responsive syndrome related to auditory nerve vascular compression. ORL J Otorhinolaryngol Relat Spec 2006;68(1):43-46
84. Mardini MK. Ear-clicking "tinnitus" responding to carbamazepine. N Engl J Med 1987;317(24):1542
85. Zheng Y, Hooton K, Smith PF, Darlington CL. Carbamazepine reduces the behavioural manifestations of tinnitus following salicylate treatment in rats. Acta Otolaryngol 2008;128(1):48-52
86. Zapp JJ. Gabapentin for the treatment of tinnitus: A case report. Ear Nose Throat J 2001;80(2):114-116
87. Shulman A. Gabapentin and tinnitus relief. Int Tinnitus J 2008;14(1):1-5
88. Bauer CA, Brozoski TJ. Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model. J Assoc Res Otolaryngol 2001;2(1):54-64
89. Witsell DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: A pilot study. Otol Neurotol 2007;28(1):11-15
90. Bakhshaee M, Ghasemi M, Azarpazhooh M, et al. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: A pilot study. Eur Arch Otorhinolaryngol 2008;265(5):525-530
91. Piccirillo JF, Finnell J, Vlahiotis A, et al. Relief of idiopathic subjective tinnitus: is gabapentin effective? Arch Otolaryngol Head Neck Surg 2007;133(4):390-397
92. Bauer CA, Brozoski TJ. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope 2006;116(5):675-681
93. Brozoski TJ, Spires TJ, Bauer CA. Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model. J Assoc Res Otolaryngol 2007;8(1):105-118
94. Willmore LJ, Abelson MB, Ben-Menachem E, et al. Vigabatrin: 2008 update. Epilepsia 2009;50(2):163-173
95. Oestreicher E, Arnold W, Ehrenberger K, Felix D. Memantine suppresses the glutamatergic neurotransmission of mammalian inner hair cells. ORL J Otorhinolaryngol Relat Spec 1998;60(1):18-21
96. Guitton MJ, Caston J, Ruel J, et al. Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci 2003;23(9):3944-3952
97. Guitton MJ, Dudai Y. Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma. Neural Plast 2007;2007:80904
98. Jastreboff PJ, Brennan JF, Coleman JK, Sasaki CT. Phantom auditory sensation in rats: An animal model for tinnitus. Behav Neurosci 1988;102(6):811-822
99. Peng BG, Chen S, Lin X. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci Lett 2003;343(1):21-24
100. Ehrenberger K, Felix D. Receptor pharmacological models for inner ear therapies with emphasis on glutamate receptors: A survey. Acta Otolaryngol 1995;115:236-240
101. Denk DM, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol 1997;117(6):825-830
102. Domeisen H, Hotz MA, Hausler R. Caroverine in tinnitus treatment. Acta Otolaryngol 1998;118(4):606-608
103. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003;9(3):275-308
104. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl- cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001;306(1-2):81-84
105. Oliver D, Ludwig J, Reisinger E, et al. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. Mol Pharmacol 2001;60(1):183-189
106. Lobarinas E, Yang G, Sun W, et al. Salicylate- and quinine-induced tinnitus and effects of memantine. Acta Otolaryngol Suppl 2006;(556):13-19
107. Figueiredo RR, Langguth B, de Oliveira PM, de Azevedo AA. Tinnitus treatment with memantine. Otolaryngol Head Neck Surg 2008;138(4):492-496
108. Salembier L, De Ridder D, Van de Heyning PH. The use of flupirtine in treatment of tinnitus. Acta Otolaryngol Suppl 2006;556:93-95
109. Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005;72(9):1775-1780
110. Azevedo AA, Figueiredo RR. Treatment of tinnitus with acamprosate. Prog Brain Res 2007;166:273-277
111. Available from: http://clinicaltrials.gov/ct2/show/NCT00596531
112. Jastreboff PJ, Hazell JW. A neurophysiological approach to tinnitus: clinical implications. Br J Audiol 1993;27(1):7-17
113. Lockwood AH, Salvi RJ, Coad ML, et al. The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity. Neurology 1998;50(1):114-120
114. Larson ER, Ariano MA. D3 and D2 dopamine receptors: visualization of cellular expression patterns in motor and limbic structures. Synapse 1995;20(4):325-337
115. Memo M, Battaini F, Spano PF, Trabucchi M. Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics. Acta Psychiatr Scand 1981;63(4):314-324
116. Lopez-Gonzalez MA, Santiago AM, Esteban-Ortega F. Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway. J Otolaryngol 2007;36(4):213-219
117. Lopez-Gonzalez MA, Moliner-Peiro F, Faro-Garcia J, Esteban-Ortega F. Sulpiride plus hydroxyzine decrease tinnitus perception. Auris Nasus Larynx 2007;34(1):23-27
118. Hastak SM. Treatment of memory impairment, vertigo and tinnitus in the elderly with piribedil in an Indian general practice setting. J Indian Med Assoc 2003;101(8):500-501
119. Slattery WH, Fisher LM, Iqbal Z, et al. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005;133(2):251-259 (Pubitemid 41125677)
120. Azevedo AA, Langguth B, de Oliveira PM, Figueiredo RR. Tinnitus treatment with piribedil guided by electrocochleography and acoustic otoemisions. Otol Neurotol In press 2009
121. Slattery WH, Fisher LM, Iqbal Z, Liu N. Oral steroid regimens for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132(1):5-10 (Pubitemid 40052664)
122. Haynes DS, O'malley M, Cohen S, et al. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117(1):3-15
123. Wei BPC, Mubiru S, O'leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2006;(1)
124. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L: chemistry, efficacy, safety, and uses. J Food Sci 2008;73(1):R14-9
125. Morgenstern C, Biermann E. The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus. Int J Clin Pharmacol Ther 2002;40(5):188-197
126. Holstein N. Ginkgo special extract EGb 761 in tinnitus therapy. An overview of results of completed clinical trials. Fortschr Med Orig 2001;118:157-164
127. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: Double blind, placebo controlled trial. BMJ 2001;322(7278):73
128. Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: A randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci 2004;29(3):226-231
129. Hilton M, Stuart E. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev 2004;2:CD003852
130. Jan JE, Reiter RJ, Wasdell MB, Bax M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res 2009;46(1):1-7
131. Seggie J, Werstiuk ES, Grota L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuropsychopharmacol Biol Psychiatry 1987;11(2-3):325-334
132. Berra B, Rizzo AM. Melatonin: circadian rhythm regulator, chronobiotic, antioxidant and beyond. Clin Dermatol 2009;27(2):202-209
133. Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000;28(2):73-80
134. Bas E, Martinez-Soriano F, Lainez JM, Marco J. An experimental comparative study of dexamethasone, melatonin and tacrolimus in noise-induced hearing loss. Acta Otolaryngol 2009;129(4):385-389
135. Megwalu UC, Finnell JE, Piccirillo JF. The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg 2006;134(2):210-213
136. Rosenberg SI, Silverstein H, Rowan PT, Olds MJ. Effect of melatonin on tinnitus. Laryngoscope 1998;108(3):305-310
137. McFadden SL, Ding D, Burkard RF, et al. Cu/Zn SOD deficiency potentiates hearing loss and cochlear pathology in aged 129,CD-1 mice. J Comp Neurol 1999;413(1):101-112
138. Zirpel L, Parks TN. Zinc inhibition of group I mGluR-mediated calcium homeostasis in auditory neurons. J Assoc Res Otolaryngol 2001;2(2):180-187
139. Shambaugh GE. Zinc for tinnitus, imbalance, and hearing loss in the elderly. Am J Otol 1986;7(6):476-477
140. Coelho CB, Tyler R, Hansen M. Zinc as a possible treatment for tinnitus. Prog Brain Res 2007;166:279-285
141. Paaske PB, Pedersen CB, Kjems G, Sam IL. Zinc in the management of tinnitus. Placebo-controlled trial. Ann Otol Rhinol Laryngol 1991;100(8):647-649
142. Yetiser S, Tosun F, Satar B, et al. The role of zinc in management of tinnitus. Auris Nasus Larynx 2002;29(4):329-333
143. Roth SH. Misoprostol in the prevention of NSAID-induced gastric ulcer: A multicenter, double-blind, placebo-controlled trial. J Rheumatol Suppl 1990;20:20-24
144. Briner W, House J, O'leary M. Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus. Arch Otolaryngol Head Neck Surg 1993;119(6):652-654
145. Yilmaz I, Akkuzu B, Cakmak O, Ozluoglu LN. Misoprostol in the treatment of tinnitus: A double-blind study. Otolaryngol Head Neck Surg 2004;130(5):604-610
146. Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004;9(1):1-17
147. Olzowy B, Canis M, Hempel JM, et al. Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial. Otol Neurotol 2007;28(4):455-458
148. Scriabine A, van den KW. Pharmacology of nimodipine. A review. Ann NY Acad Sci 1988;522:698-706
149. Keyrouz SG, Diringer MN. Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care 2007;11(4):220
150. Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder. J Clin Psychiatry 1995;56(7):330
151. Jastreboff PJ, Brennan JF, Sasaki CT. Quinine-induced tinnitus in rats. Arch Otolaryngol Head Neck Surg 1991;117(10):1162-1166
152. Theopold HM. Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear?. Laryngol Rhinol Otol (Stuttg) 1985;64(12):609-613
153. Davies E, Knox E, Donaldson I. The usefulness of nimodipine, an L-calcium channel antagonist, in the treatment of tinnitus. Br J Audiol 1994;28(3):125-129
154. Hutcheon DE, Leonard G. Diuretic and antihypertensive actions of furosemide. J Clin Pharmacol J New Drugs 1967;7(1):26-33
155. Shiozaki A, Miyazaki H, Niisato N, et al. Furosemide, a blocker of Na+/K+/2Cl-cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci 2006;56(6):401-406
156. Sakaguchi N, Crouch JJ, Lytle C, Schulte BA. Na-K-Cl cotransporter expression in the developing and senescent gerbil cochlea. Hear Res 1998;118(1-2):114-122
157. Chen H, Sun D. The role of Na-K-Cl co-transporter in cerebral ischemia. Neurol Res 2005;27(3):280-286
158. Rybak LP, Morizono T. Effect of furosemide upon endolymph potassium concentration. Hear Res 1982;7(2):223-231
159. Futaki T, Kitahara M, Morimoto M. A comparison of the furosemide and glycerol tests for Meniere's disease. With special reference to the bilateral lesion. Acta Otolaryngol 1977;83(3-4):272-278
160. Kuchar DL, O'rourke MF. High dose furosemide in refractory cardiac failure. Eur Heart J 1985;6(11):954-958
161. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006;333(7565):420
162. Filipo R, Barbara M, Cordier A, et al. Osmotic drugs in the treatment of cochlear disorders: A clinical and experimental study. Acta Otolaryngol 1997;117(2):229-231
163. McCabe BF. Central aspects of drugs for motion sickness and vertigo. Adv Otorhinolaryngol 1973;20:458-469
164. Kranke P, Morin AM, Roewer N, et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesth Analg 2002;95(1):133-143, table (Pubitemid 34705567)
165. Wallhausser-Franke E, Cuautle-Heck B, et al. Scopolamine attenuates tinnitus-related plasticity in the auditory cortex. Neuroreport 2006;17(14):1487-1491
166. Lobarinas E, Sun W, Stolzberg D, et al. Human brain imaging of tinnitus and animal models. Semin Hear 2008;29(4):333-349
167. Timmerman H. Calcium modulation and clinical effect. Profile of cyclandelate. Drugs 1987;33(Suppl 2):1-4
168. Memin Y. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients. Drugs 1987;33(Suppl 2):120-124
169. Hester TO, Theilman G, Green W, Jones RO. Cyclandelate in the management of tinnitus: A randomized, placebo-controlled study. Otolaryngol Head Neck Surg 1998;118(3 Pt 1):329-332
170. Stidham KR, Solomon PH, Roberson JB. Evaluation of botulinum toxin A in treatment of tinnitus. Otolaryngol Head Neck Surg 2005;132(6):883-889
171. Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor: A report of five cases and a review of the literature. J Neurol 2006;253(7):857-860
172. Adjamian P, Sereda M, Hall DA. The mechanisms of tinnitus: Perspectives from human functional neuroimaging. Hear Res 2009;253:15-31
173. Turner JG. Behavioral measures of tinnitus in laboratory animals. Prog Brain Res 2007;166:147-156
174. Arnold W, Bartenstein P, Oestreicher E, et al. Focal metabolic activation in the predominant left auditory cortex in patients suffering from tinnitus: A PET study with [18F]deoxyglucose. ORL J Otorhinolaryngol Relat Spec 1996;58:195-199
175. Muhlnickel W, Elbert T, Taub E, Flor H. Reorganization of auditory cortex in tinnitus. Proc Natl Acad Sci USA 1998;95:10340-10343
176. Sun W, Lu J, Stolzberg D, et al. Salicylate increases the gain of the central auditory system. Neuroscience 2009;159(1):325-334
177. Moller AR. The role of neural plasticity in tinnitus. Prog Brain Res 2007;166:37-45
178. De Ridder D, Verstraeten E, Van der KK, et al. Transcranial magnetic stimulation for tinnitus: influence of tinnitus duration on stimulation parameter choice and maximal tinnitus suppression. Otol Neurotol 2005;26(4):616-619
179. De Ridder D, van der Loo E, Van der Kelen K, et al. Do tonic and burst TMS modulate the lemniscal and extralemniscal system differentially? Int J Med Sci 2007;4(5):242-246
180. Tyler R, Coelho C, Tao P, et al. Identifying tinnitus subgroups with cluster analysis. Am J Audiol 2008;17(2):S176-84
181. Tyler RS, Oleson J, Noble W, et al. Clinical trials for tinnitus: Study populations, designs, measurement variables, and data analysis. Prog Brain Res 2007;166:499-509
182. Elgoyhen AB, Vetter DE, Katz E, et al. Alpha10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci USA 2001;98(6):3501-3506
183. Elgoyhen AB, Johnson DS, Boulter J, et al. Alpha 9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994;79(4):705-715
184. Plazas PV, Savino J, Kracun S, et al. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur J Pharmacol 2007;566(1-3):11-19
185. Available from: http://clinicaltrials.gov/ct2/show/NCT00405886
186. Available from: http://clinicaltrials.gov/ct2/show/NCT00739635, http://clinicaltrials.gov/ct2/show/NCT00772980, http://clinicaltrials.gov/ct2/ show/NCT00827008
187. Available from: http://clinicaltrials.gov/ct2/show/NCT00860808
188. Sun W, Ding DL, Wang P, et al. Substance P inhibits potassium and calcium currents in inner ear spiral ganglion neurons. Brain Res 2004;1012(1-2):82-92
189. Available from: http://clinicaltrials.gov/ct2/show/NCT00394056
190. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 2008;33(9):2061-2079
191. De Ridder D, Fransen H, Francois O, et al. Amygdalohippocampal involvement in tinnitus and auditory memory. Acta Otolaryngol Suppl 2006;556:50-53
192. Yang G, Lobarinas E, Zhang L, et al. Salicylate induced tinnitus: behavioral measures and neural activity in auditory cortex of awake rats. Hear Res 2007;226(1-2):244-253
193. Lobarinas E, Sun W, Cushing R, Salvi R. A novel behavioral paradigm for assessing tinnitus using schedule-induced polydipsia avoidance conditioning (SIP-AC). Hear Res 2004;190(1-2):109-114
194. Hurko O, Ryan JL. Translational research in central nervous system drug discovery. Neuro Rx 2005;2(4):671-682
195. Meikle MB, Vernon J, Johnson RM. The perceived severity of tinnitus. Some observations concerning a large population of tinnitus clinic patients. Otolaryngol Head Neck Surg 1984;92(6):689-696
196. Jakes SC, Hallam RS, Chambers C, Hinchcliffe R. A factor analytical study of tinnitus complaint behaviour. Audiology 1985;24(3):195-206
197. Newman CW, Sandridge SA, Jacobson GP. Psychometric adequacy of the Tinnitus Handicap Inventory (THI) for evaluating treatment outcome. J Am Acad Audiol 1998;9(2):153-160
198. Goebel G, Hiller W. The tinnitus questionnaire. A standard instrument for grading the degree of tinnitus. Results of a multicenter study with the tinnitus questionnaire Hno 1994;42:166-172
199. Kuk FK, Tyler RS, Russell D, Jordan H. The psychometric properties of a tinnitus handicap questionnaire. Ear Hear 1990;11(6):434-445